Recent Finacing
Recent Raise
Intra Cellular Therapies develops ITI-007, a multimodal CNS drug combining 5‑HT2A interaction, dopamine receptor phosphoprotein modulation and serotonin reuptake inhibition, in Phase II trials for schizophrenia and other indications.
Focus Areas
Total Raised
Funding round